Jupiter Neurosciences Inc... (JUNS)
0.73
-0.02 (-2.12%)
At close: Mar 25, 2025, 3:57 PM
0.75
3.22%
Pre-market: Mar 26, 2025, 07:14 AM EDT
-2.12% (1D)
| Bid | 0.7 |
| Market Cap | 24.07M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -1.43M |
| EPS (ttm) | -0.02 |
| PE Ratio (ttm) | -36.36 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | 0.8 |
| Volume | 36,912 |
| Avg. Volume (20D) | 701,932 |
| Open | 0.75 |
| Previous Close | 0.75 |
| Day's Range | 0.72 - 0.75 |
| 52-Week Range | 0.55 - 19.51 |
| Beta | 0.00 |
About JUNS
Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation. It is developing JNS101 that is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis...
Industry Biotechnology
Sector Healthcare
IPO Date Jan 18, 2022
Employees 4
Stock Exchange NASDAQ
Ticker Symbol JUNS
Website https://www.jupiterorphan.com